FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
About
ceo
Dr. Eliot Richard Forster M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.f-star.comexchange
NASDAQ
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-s...
CIK
0001566373
ISIN
US30315R1077
CUSIP
30315R107
Address
Eddeva B920
Phone
44 1223 497400
Country
GB
Employee
84
IPO Date
May 6, 2016
Summary
CIK
0001566373
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
30315R107
ISIN
US30315R1077
Country
GB
Price
7.12
Beta
-0.35
Volume Avg.
747.28k
Market Cap
156.51M
Shares
-
52-Week
2.07-7.12
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.89
P/B
-
Website
https://www.f-star.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest FSTX News
It looks like there's no news available.
